Properties for 17-AAG
|Shipping to||Not USA/Canada|
|PDF datasheet||View Datasheet|
|Manufacturer||Novus Biologicals Inc.|
|Add. information||Synthetic 17-AAG
Soluble in DMSO (>20mg/mL) or mehtanol (10mg/mL)
|Application||, Synthetic 17-AAG Soluble in DMSO (>20mg/mL) or mehtanol (10mg/mL) Purple solid|
|Background||Glendanamycin (GA), a benzoquinone ansamycin antibiotic, interferes with the action of Hsp90 leading to degradation of Hsp90 client proteins. GA itself however has undesirable properties such as poor aqueous solubility and liver toxicity; therefore, numerous analogs have been synthesized, such as 17-AAG(1). 17-AAG is an HSP-90 inhibitor that displays a 100-fold higher affinity for HSP-90 derived from tumor cells compared to HSP-90 from normal cells(2). 17-AAG inhibits Akt activation and expression in tumors and synergizes with a number of antitumor agents such as taxol(3), cisplatin(4) and UCN-01 (400 nM 17-AAG, U937 cells)(5).|
|General Readings||1. Neckers L. (2002) Trends Mol Med. 84: S55-61.
2. Kamal A., et al.(2003) Nature 425: 407.
3. Solit D.B., et al.(2003) Cancer Res. 63: 2139.
4. Vasilevskaya I.A., et al. (2003) Mol.Pharmacol. 2003
5. Jia W., et al.(2003) Blood 102: 1824.
|Storage||Store at -20C. Avoid freeze-thaw cycles.|